Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y₁₂ inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).